Abstract
Introduction: Although the first results from studies suggested important benefits regarding blood pressure (BP) control in resistant hypertension by the use of diverse systems of renal denervation (RDN) in the setting of resistant hypertension, the Symplicity HTN-3, randomized sham-controlled trial reduced the enthusiasm and led to a more critical approach towards this neuromodulation innovative therapy. Nowadays there is an ongoing research attempt to justify the pathophysiological background of RDN since overdrive of the sympathetic nervous system is one of the key mechanisms leading to the development and progression of the hypertensive and cardiovascular diseases.
Conclusion: Future RDN trials based on the clinical findings and gaps from previous works will try to identify those parameters to help identify better BP response, target the most suitable population and conclude whether this interventional approach can contribute to the clinical problem of uncontrolled hypertension.
Keywords: Renal denervation, resistant hypertension, blood pressure response, Symplicity HTN-3, BP, cardiovascular disease.
Graphical Abstract
Current Vascular Pharmacology
Title:Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?
Volume: 16 Issue: 1
Author(s): Costas Tsioufis*, Kyriakos Dimitriadis, Athanasios Kordalis, Michalis Doumas, Dimitris Konstantinidis, Theodoros Kalos, Felix Mahfoud, Vasilios Papademetriou and Dimitrios Tousoulis
Affiliation:
- First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens,Greece
Keywords: Renal denervation, resistant hypertension, blood pressure response, Symplicity HTN-3, BP, cardiovascular disease.
Abstract: Introduction: Although the first results from studies suggested important benefits regarding blood pressure (BP) control in resistant hypertension by the use of diverse systems of renal denervation (RDN) in the setting of resistant hypertension, the Symplicity HTN-3, randomized sham-controlled trial reduced the enthusiasm and led to a more critical approach towards this neuromodulation innovative therapy. Nowadays there is an ongoing research attempt to justify the pathophysiological background of RDN since overdrive of the sympathetic nervous system is one of the key mechanisms leading to the development and progression of the hypertensive and cardiovascular diseases.
Conclusion: Future RDN trials based on the clinical findings and gaps from previous works will try to identify those parameters to help identify better BP response, target the most suitable population and conclude whether this interventional approach can contribute to the clinical problem of uncontrolled hypertension.
Export Options
About this article
Cite this article as:
Tsioufis Costas *, Dimitriadis Kyriakos, Kordalis Athanasios , Doumas Michalis , Konstantinidis Dimitris , Kalos Theodoros, Mahfoud Felix , Papademetriou Vasilios and Tousoulis Dimitrios , Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?, Current Vascular Pharmacology 2018; 16 (1) . https://dx.doi.org/10.2174/1570161115666170426151649
DOI https://dx.doi.org/10.2174/1570161115666170426151649 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Ursolic Acid Attenuates HMGB1-induced LOX-1 Expression in Vascular Endothelial Cells in vitro and Inhibits Atherogenesis in Hypercholesterolemic Mice in vivo
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Adipokines as Potential Biomarkers in the Neurorehabilitation of Obese Stroke Patients
Current Neurovascular Research New Insights in Congenital Diaphragmatic Hernia
Current Respiratory Medicine Reviews Effect of GLP-1 Based Therapies on Diabetic Dyslipidemia
Current Diabetes Reviews Vasospastic Angina and Ca Channel Blockers
Current Hypertension Reviews New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry Evidence for Pleiotropic Effects of Statins in Clinical Trials
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design An Eco-Friendly and Highly Efficient Synthesis of Pyrimidinones Using a TiO2-CNTs Nanocomposite Catalyst
Letters in Organic Chemistry Patents in Diagnosis of Preeclampsia
Recent Patents on Biomarkers Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Current Drug Targets All for Statins and Statins for All; An Update
Current Pharmaceutical Design The Activated Endocannabinoid System in Atherosclerosis: Driving Force or Protective Mechanism?
Current Drug Targets The Therapeutic Potential of Induced Pluripotent Stem Cells After Stroke: Evidence from Rodent Models
Current Stem Cell Research & Therapy Cardiovascular Disease in the Rheumatic Diseases: How Systemic Inflammation May Contribute to Atherogenesis
Current Rheumatology Reviews Targeting Soluble Epoxide Hydrolase for Inflammation and Pain - An Overview of Pharmacology and the Inhibitors
Inflammation & Allergy - Drug Targets (Discontinued) Modulation of Vascular Function by Perivascular Adipose Tissue: Sex Differences
Current Pharmaceutical Design